Healthcare Playbook: JPM Day One 1/8/24
Healthcare Playbook -JPM Day One 1//24 Momentum resumed in many small cap biotech stocks today helped by dealmaking. The IBB was up 2.4% to $139.39 and the equal weighted small cap XBI was up 4.6% to $93.42. Among the big movers on our SMID Focus list below are: Caribou (CRBU) up 19.09% to...
Large Cap Biopharmaceuticals Baseline as of 1/7/24
Large Cap Biopharmaceuticals as of 1/7/24 prior to JPM Most healthcare ETFs and Large Caps are up since the 10/8/23 lows. We will look at these valuations after JPM and Q4 earnings.The trend for the Life Science and Biopharma sector is usually up for Q4 in anticipation of JPM and Q4 earnings...
Life Science Mutual Funds Compared to ETFs…January 2024 and Retrospective-Part I
Life Science Mutual Funds Compared to ETFs We have written about Life Science Funds vs ETFs in our past articles. Life science funds have been in a bear market since the recent peak in Q3 2021. The period from 4/20 through 2/21 were good years for biotech and medtech driven by innovation needs...
Small Caps Are on a Tear Including Speculative Biotechs:Update-4…Strong Start for healthcare stocks in 2024
Update-4 1/3/23-1p EST,...Shift in biopharma toward large cap biotechs. Review small cap trades for profit taking. Our favorite large caps are: ABBV, GILD, LLY, MRK, REGN, VRTX; more speculative picks are BBII and PFE. We will update our Large Cap Biopharma metrics list this weekend. Many...
Small Caps Can Continue to Rally But Needs Deal Flow…Update-3
Licensing and M&A Through the JPM Meeting in Early January 2024 Should Support Gains Update-3 12/22 ,,,Added Catalyst (Pharmaceuticals (CPRX)at 16+, is focused on rare neurological and epileptic diseases. Karuna Therapeutics (KRTX) up 47% to $316 handle on Bristol Myers (BMY) $14B buyout...